- Home
- RADX vs COCH Comparison
RADX vs COCH Comparison
Compare RADX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RADX
- COCH
- Stock Information
- Founded
- RADX 2021
- COCH 1995
- Country
- RADX Australia
- COCH United States
- Employees
- RADX N/A
- COCH N/A
- Industry
- RADX
- COCH Blank Checks
- Sector
- RADX
- COCH Finance
- Exchange
- RADX NYSE
- COCH Nasdaq
- Market Cap
- RADX 32.5M
- COCH 31.6M
- IPO Year
- RADX N/A
- COCH N/A
- Fundamental
- Price
- RADX $4.25
- COCH $1.47
- Analyst Decision
- RADX Strong Buy
- COCH Strong Buy
- Analyst Count
- RADX 2
- COCH 2
- Target Price
- RADX $13.50
- COCH $9.25
- AVG Volume (30 Days)
- RADX 22.4K
- COCH 25.8K
- Earning Date
- RADX 02-26-2025
- COCH 08-11-2025
- Dividend Yield
- RADX N/A
- COCH N/A
- EPS Growth
- RADX N/A
- COCH N/A
- EPS
- RADX N/A
- COCH N/A
- Revenue
- RADX $204,609.00
- COCH $212,000.00
- Revenue This Year
- RADX N/A
- COCH $8.04
- Revenue Next Year
- RADX N/A
- COCH $15.39
- P/E Ratio
- RADX N/A
- COCH N/A
- Revenue Growth
- RADX N/A
- COCH N/A
- 52 Week Low
- RADX $3.50
- COCH $1.21
- 52 Week High
- RADX $50.82
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- RADX N/A
- COCH 48.45
- Support Level
- RADX N/A
- COCH $1.40
- Resistance Level
- RADX N/A
- COCH $1.58
- Average True Range (ATR)
- RADX 0.00
- COCH 0.10
- MACD
- RADX 0.00
- COCH 0.01
- Stochastic Oscillator
- RADX 0.00
- COCH 43.74
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.